{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-08-03",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "third_party_flag": "N",
      "life_sustain_support_flag": "N",
      "gmp_exempt_flag": "N",
      "summary_malfunction_reporting": "Ineligible",
      "product_code": "SBB",
      "openfda": {
        "pma_number": [
          "P230001"
        ],
        "registration_number": [
          "3026996410",
          "3007871198",
          "1938173"
        ],
        "fei_number": [
          "3026996410",
          "3007871198",
          "1938173"
        ]
      },
      "review_panel": "PA",
      "medical_specialty": "",
      "device_name": "System, Colorectal Neoplasia, Rna Markers And Hemoglobin Detection",
      "review_code": "",
      "unclassified_reason": "",
      "medical_specialty_description": "Unknown",
      "device_class": "3",
      "definition": "The colorectal neoplasia RNA and hemoglobin assay is a non-invasive, qualitative in vitro diagnostic intended for the detection of colorectal neoplasia associated RNA markers and for the presence of occult hemoglobin in human stool.  The test is to aid in the detection of colorectal cancer (CRC) and advanced adenomas (AA).  The test is not a replacement for diagnostic colonoscopy.  It is indicated for use in adults 45 years or older, who are typical average-risk candidates for colorectal cancer (CRC) screening.  A positive result may indicate the presence of CRC or AA and should be followed by a diagnostic colonoscopy.",
      "regulation_number": "",
      "implant_flag": "N",
      "submission_type_id": "2"
    }
  ]
}